Oncology Central

Musings on value frameworks in cancer

0

Drug pricing is all over the news lately. Rarely does a day go by without seeing headlines like “The inexplicable and relentless rise of cancer drug prices” (Washington Post, 2 May 2016) or “Doctors Object to High Cancer-Drug prices” (Wall Street Journal, 23 July 2015). These are only a couple of examples of news outlets proclaiming that spending on cancer therapies is unsustainable. Implicit in the panic about cancer drug spending is the fundamental value question: “What is a cancer therapy worth?”

To view restricted content, please:
Share:

Leave A Comment